Last reviewed 2026-05-19 · How we verify

CN-sourced ipilimumab

Shanghai Henlius Biotech · Phase 1 active Small molecule ✓ Verified May 2026

CN-sourced ipilimumab is a Small molecule drug developed by Shanghai Henlius Biotech. It is currently in Phase 1 development.

CN-sourced ipilimumab is an antibody that inhibits the Cytotoxic T-lymphocyte protein 4. It is being studied in a Phase I clinical trial (NCT06159101) to compare its pharmacokinetics, safety, tolerability, and immunogenicity with EU-sourced ipilimumab in healthy male volunteers.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CN-sourced ipilimumab
Sponsor	Shanghai Henlius Biotech
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CN-sourced ipilimumab CI brief — competitive landscape report
CN-sourced ipilimumab updates RSS · CI watch RSS
Shanghai Henlius Biotech portfolio CI

Frequently asked questions about CN-sourced ipilimumab

What is CN-sourced ipilimumab?

CN-sourced ipilimumab is a Small molecule drug developed by Shanghai Henlius Biotech.

Who makes CN-sourced ipilimumab?

CN-sourced ipilimumab is developed by Shanghai Henlius Biotech (see full Shanghai Henlius Biotech pipeline at /company/shanghai-henlius-biotech).

What development phase is CN-sourced ipilimumab in?

CN-sourced ipilimumab is in Phase 1.

Manufacturer: Shanghai Henlius Biotech — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing